DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,115 filers reported holding DANAHER CORPORATION in Q3 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,029,939 | -7.5% | 1,072,269 | -10.5% | 0.31% | -3.1% |
| Q2 2023 | $287,668,560 | -4.8% | 1,198,619 | -0.1% | 0.32% | -6.9% |
| Q1 2023 | $302,281,402 | -5.0% | 1,199,339 | +0.1% | 0.35% | -9.2% |
| Q4 2022 | $318,045,355 | -1.9% | 1,198,272 | -4.5% | 0.38% | -8.4% |
| Q3 2022 | $324,081,000 | +3.5% | 1,254,721 | +1.6% | 0.42% | +11.8% |
| Q2 2022 | $313,179,000 | -26.3% | 1,235,324 | -14.7% | 0.37% | -14.3% |
| Q1 2022 | $424,808,000 | +24.1% | 1,448,226 | +39.2% | 0.44% | +23.9% |
| Q4 2021 | $342,281,000 | +13.1% | 1,040,338 | +4.7% | 0.35% | +4.5% |
| Q3 2021 | $302,565,000 | +13.0% | 993,838 | -0.4% | 0.34% | +16.7% |
| Q2 2021 | $267,864,000 | +33.4% | 998,152 | +11.9% | 0.29% | +25.8% |
| Q1 2021 | $200,856,000 | +58.8% | 892,379 | +56.7% | 0.23% | +46.8% |
| Q4 2020 | $126,487,000 | +14.8% | 569,401 | +11.3% | 0.16% | +13.9% |
| Q3 2020 | $110,161,000 | -3.5% | 511,592 | -20.7% | 0.14% | -11.0% |
| Q2 2020 | $114,121,000 | +22.2% | 645,367 | -4.4% | 0.15% | +0.7% |
| Q1 2020 | $93,410,000 | -37.6% | 674,877 | -30.8% | 0.15% | -26.4% |
| Q4 2019 | $149,673,000 | -11.6% | 975,195 | -16.8% | 0.21% | -18.8% |
| Q3 2019 | $169,385,000 | -10.6% | 1,172,791 | -11.6% | 0.26% | -10.5% |
| Q2 2019 | $189,512,000 | -2.0% | 1,326,000 | -9.5% | 0.29% | -5.6% |
| Q1 2019 | $193,442,000 | +37.9% | 1,465,239 | +7.7% | 0.30% | +21.7% |
| Q4 2018 | $140,303,000 | +46.1% | 1,360,575 | +53.9% | 0.25% | +75.4% |
| Q3 2018 | $96,044,000 | +43.1% | 883,904 | +30.0% | 0.14% | +40.6% |
| Q2 2018 | $67,095,000 | +223.2% | 679,932 | +220.7% | 0.10% | +77.2% |
| Q1 2018 | $20,760,000 | +30.7% | 212,031 | +23.9% | 0.06% | +29.5% |
| Q4 2017 | $15,889,000 | +428.6% | 171,182 | +388.5% | 0.04% | +388.9% |
| Q3 2017 | $3,006,000 | +15.0% | 35,042 | +5.1% | 0.01% | +12.5% |
| Q3 2016 | $2,613,000 | -80.3% | 33,328 | -74.6% | 0.01% | -81.0% |
| Q2 2016 | $13,237,000 | -25.7% | 131,064 | -30.2% | 0.04% | -23.6% |
| Q1 2016 | $17,821,000 | -35.5% | 187,869 | -36.9% | 0.06% | -34.5% |
| Q4 2015 | $27,643,000 | -35.4% | 297,612 | -40.7% | 0.08% | -43.6% |
| Q3 2015 | $42,763,000 | +143.1% | 501,856 | +144.2% | 0.15% | +166.1% |
| Q2 2015 | $17,591,000 | -50.1% | 205,536 | -50.5% | 0.06% | -50.9% |
| Q1 2015 | $35,263,000 | -6.3% | 415,338 | -5.4% | 0.11% | -12.3% |
| Q4 2014 | $37,627,000 | +24.4% | 439,002 | +10.3% | 0.13% | +12.1% |
| Q3 2014 | $30,236,000 | -61.2% | 397,947 | -59.8% | 0.12% | -60.3% |
| Q2 2014 | $77,901,000 | -15.7% | 989,470 | -19.7% | 0.29% | -12.8% |
| Q1 2014 | $92,456,000 | +66.4% | 1,232,745 | +71.3% | 0.34% | +49.6% |
| Q4 2013 | $55,553,000 | +18.1% | 719,597 | +6.0% | 0.22% | -0.4% |
| Q3 2013 | $47,056,000 | -18.0% | 678,821 | -25.1% | 0.22% | -30.8% |
| Q2 2013 | $57,391,000 | – | 906,658 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |